SCHEMBL9923159

SCHEMBL9923159

CS(=O)(=O)c1ccc2ccn(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.49
MAPT P10636 6/20 0.40
FBP1 P09467 1/20 0.39
RECQL P46063 2/20 0.38
KDM4E B2RXH2 2/20 0.38
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
HPGD P15428 1/20 0.35
GAA P10253 1/20 0.35
LMNA P02545 3/20 0.35
HTT P42858 2/20 0.35
CNR1 P21554 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9922294 0.91 P2RY12 (0.47) P2RY12MAPTFBP1MEN1KMT2A
SCHEMBL9922289 0.89 P2RY12 (0.49) P2RY12MAPTFBP1RECQLMEN1
SCHEMBL9922340 0.89 P2RY12 (0.43) P2RY12MAPTFBP1RECQLKDM4E
SCHEMBL9922503 0.88 FBP1 (0.42) P2RY12MAPTFBP1RECQLKDM4E
SCHEMBL9923158 0.88 P2RY12 (0.52) P2RY12MAPTFBP1RECQLRAB9A
SCHEMBL9923157 0.88 P2RY12 (0.48) P2RY12MAPTFBP1RECQLMEN1
SCHEMBL13638506 0.88 P2RY12 (0.48) P2RY12MAPTFBP1RECQLNPC1
SCHEMBL9922636 0.88 P2RY12 (0.48) P2RY12MAPTFBP1RECQLKDM4E
SCHEMBL9920094 0.87 P2RY12 (0.48) P2RY12MAPTFBP1RECQLKDM4E
SCHEMBL9923167 0.87 P2RY12 (0.48) P2RY12MAPTFBP1RECQLMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524721-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2013-09-03 US disclosed
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-06-14 US disclosed
US-8067428-B2 Platelet ADP receptor inhibitors PORTOLA PHARMACEUTICALS, INC. (US) 2011-11-29 US disclosed
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS PORTOLA PHARMACEUTICALS, INC. (US) 2010-09-16 US disclosed
US-7622474-B2 Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis PORTOLA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-7358257-B2 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents PORTOLA PHARMACEUTICALS, INC. (US) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234350-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 19/4885MAPT 4832/4885FBP1 1584/4885
US-20120149688-A1 PLATELET ADP RECEPTOR INHIBITORS TBXA2R, GP6, P2RY6 P2RY12 18/4885MAPT 4832/4885FBP1 1579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.